Gilead Sciences, Inc. (GILD) Stock Analysis
Healthcare · Drug Manufacturers - General · NasdaqGS
Gilead Sciences, Inc. (GILD) posted $29.44B in revenue for fiscal 2025 (up 2.4% year over year), at a 28.9% net margin, and has compounded revenue about 3.6%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Gilead Sciences, Inc.
Gilead Sciences, Inc. has grown revenue from $30.39B to $29.44B over the last 10 fiscal years, compounding about 3.6% a year. The most recent year was up 2.4%, so growth has cooled from its longer-run pace.
Net margin sits at 28.9%, up 27.2 points year over year on a 78.8% gross margin. It carries about $27.74B of total debt.
At today's valuation the market is pricing in roughly 5.6% annual free-cash-flow growth — versus the 4.7% it actually delivered over the last five years, broadly in line with what it has delivered.
Synthesised from Gilead Sciences, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Gilead Sciences, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.39B | $26.11B | $22.13B | $22.45B | $24.69B | $27.30B | $27.28B | $27.12B | $28.75B | $29.44B |
| Gross profit | $26.13B | $21.74B | $17.27B | $17.77B | $20.12B | $20.70B | $21.62B | $20.62B | $22.50B | $23.21B |
| Net income | $13.50B | $4.63B | $5.46B | $5.39B | $123.00M | $6.22B | $4.59B | $5.67B | $480.00M | $8.51B |
| Net margin | 44.4% | 17.7% | 24.7% | 24.0% | 0.5% | 22.8% | 16.8% | 20.9% | 1.7% | 28.9% |
Source: Gilead Sciences, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
Gilead Sciences, Inc.: no obvious red flags in the filings
Our deterministic scan of the filed statements — receivables vs sales, earnings vs cash, dilution, leverage and margins — didn't flag anything. Ask about the risks →
What growth is priced into GILD stock?
At today's market cap of $161.66B, Gilead Sciences, Inc. is priced for free-cash-flow growth of about 5.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $9.46B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 4.7%/yr over the last five fiscal years and revenue 3.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Gilead Sciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track GILD in your portfolio →
Gilead Sciences, Inc. financial history by metric
Compare Gilead Sciences, Inc. with peers
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. — frequently asked questions
What is Gilead Sciences, Inc.'s revenue?
Gilead Sciences, Inc. (GILD) reported revenue of $29.44B for fiscal year 2025, up 2.4% from the prior year, according to its SEC filings.
Is Gilead Sciences, Inc. profitable?
Yes. GILD earned net income of $8.51B in fiscal 2025, a net margin of 28.9%.
What is GILD's P/E ratio?
Gilead Sciences, Inc. trades at a price-to-earnings ratio of about 17.7 based on the latest data in our nightly-refreshed cache.
How fast is Gilead Sciences, Inc. growing?
GILD's revenue grew at roughly 3.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Gilead Sciences, Inc. have?
As of fiscal year 2025, GILD carried roughly $27.74B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Gilead Sciences, Inc.'s gross margin?
GILD's gross margin was 78.8% in fiscal 2025 — gross profit of $23.21B on revenue of $29.44B.
What is Gilead Sciences, Inc.'s market cap?
Gilead Sciences, Inc. (GILD) has a market capitalization of about $161.66B, based on the latest data in our nightly-refreshed cache.
When does Gilead Sciences, Inc.'s fiscal year end?
GILD's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into GILD stock?
At today's market cap of $161.66B, Gilead Sciences, Inc. is priced for free-cash-flow growth of about 5.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $9.46B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 4.7%/yr over the last five fiscal years and revenue 3.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Gilead Sciences, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.